These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

592 related articles for article (PubMed ID: 24911993)

  • 1. Decision for biological treatment in real life is more strongly associated with the Psoriasis Area and Severity Index (PASI) than with the Dermatology Life Quality Index (DLQI).
    Hägg D; Sundström A; Eriksson M; Schmitt-Egenolf M
    J Eur Acad Dermatol Venereol; 2015 Mar; 29(3):452-6. PubMed ID: 24911993
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Analysis of three outcome measures in moderate to severe psoriasis: a registry-based study of 2450 patients.
    Norlin JM; Steen Carlsson K; Persson U; Schmitt-Egenolf M
    Br J Dermatol; 2012 Apr; 166(4):797-802. PubMed ID: 22182212
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Relationship between clinical response to therapy and health-related quality of life outcomes in patients with moderate to severe plaque psoriasis.
    Revicki DA; Willian MK; Menter A; Saurat JH; Harnam N; Kaul M
    Dermatology; 2008; 216(3):260-70. PubMed ID: 18187944
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sustained Psoriasis Area and Severity Index, Dermatology Life Quality Index and EuroQol-5D response of biological treatment in psoriasis: 10 years of real-world data in the Swedish National Psoriasis Register.
    Hjalte F; Carlsson KS; Schmitt-Egenolf M
    Br J Dermatol; 2018 Jan; 178(1):245-252. PubMed ID: 28644904
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Psoriasis Area Severity Index (PASI) and the Dermatology Life Quality Index (DLQI): the correlation between disease severity and psychological burden in patients treated with biological therapies.
    Mattei PL; Corey KC; Kimball AB
    J Eur Acad Dermatol Venereol; 2014 Mar; 28(3):333-7. PubMed ID: 23425140
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Switch to biological agent in psoriasis significantly improved clinical and patient-reported outcomes in real-world practice.
    Norlin JM; Steen Carlsson K; Persson U; Schmitt-Egenolf M
    Dermatology; 2012; 225(4):326-32. PubMed ID: 23328678
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Durable dermatology life quality index improvements in patients on biologics associated with psoriasis areas and severity index: a longitudinal study.
    Chaptini C; Quinn S; Marshman G
    Australas J Dermatol; 2016 Aug; 57(3):e72-5. PubMed ID: 26010650
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The relationship between quality of life and the severity of psoriasis in Turkey.
    Çakmur H; Derviş E
    Eur J Dermatol; 2015 Apr; 25(2):169-76. PubMed ID: 25655046
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Utility of the Dermatology Life Quality Index at initiation or switching of biologics in real-life Japanese patients with plaque psoriasis: Results from the ProLOGUE study.
    Imafuku S; Kanai Y; Murotani K; Nomura T; Ito K; Ohata C; Yamazaki F; Miyagi T; Takahashi H; Okubo Y; Saeki H; Honma M; Tada Y; Mabuchi T; Higashiyama M; Kobayashi S; Hashimoto Y; Seishima M; Kakuma T
    J Dermatol Sci; 2021 Mar; 101(3):185-193. PubMed ID: 33495058
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Complete skin clearance and Psoriasis Area and Severity Index response rates in clinical practice: predictors, health-related quality of life improvements and implications for treatment goals.
    Norlin JM; Nilsson K; Persson U; Schmitt-Egenolf M
    Br J Dermatol; 2020 Apr; 182(4):965-973. PubMed ID: 31325318
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Psychometric properties of the Chinese version of Dermatology Life Quality Index (DLQI) in 851 Chinese patients with psoriasis.
    He Z; Lu C; Basra MK; Ou A; Yan Y; Li L
    J Eur Acad Dermatol Venereol; 2013 Jan; 27(1):109-15. PubMed ID: 22145712
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dramatic impact of a Psoriasis Area and Severity Index 90 response on the quality of life in patients with psoriasis: an analysis of Japanese clinical trials of infliximab.
    Torii H; Sato N; Yoshinari T; Nakagawa H;
    J Dermatol; 2012 Mar; 39(3):253-9. PubMed ID: 22211581
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The validity and responsiveness of three quality of life measures in the assessment of psoriasis patients: results of a phase II study.
    Shikiar R; Willian MK; Okun MM; Thompson CS; Revicki DA
    Health Qual Life Outcomes; 2006 Sep; 4():71. PubMed ID: 17005043
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clear or almost clear skin improves the quality of life in patients with moderate-to-severe psoriasis: a systematic review and meta-analysis.
    Puig L; Thom H; Mollon P; Tian H; Ramakrishna GS
    J Eur Acad Dermatol Venereol; 2017 Feb; 31(2):213-220. PubMed ID: 27739123
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Severity of Psoriasis Differs Between Men and Women: A Study of the Clinical Outcome Measure Psoriasis Area and Severity Index (PASI) in 5438 Swedish Register Patients.
    Hägg D; Sundström A; Eriksson M; Schmitt-Egenolf M
    Am J Clin Dermatol; 2017 Aug; 18(4):583-590. PubMed ID: 28342016
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Psoriasis affects patient's quality of life more seriously in female than in male in Japan.
    Mabuchi T; Yamaoka H; Kojima T; Ikoma N; Akasaka E; Ozawa A
    Tokai J Exp Clin Med; 2012 Sep; 37(3):84-8. PubMed ID: 23032250
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bioelectrical phase angle and psoriasis: a novel association with psoriasis severity, quality of life and metabolic syndrome.
    Barrea L; Macchia PE; Di Somma C; Napolitano M; Balato A; Falco A; Savanelli MC; Balato N; Colao A; Savastano S
    J Transl Med; 2016 May; 14(1):130. PubMed ID: 27165166
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A detailed analysis of 'not relevant' responses on the DLQI in psoriasis: potential biases in treatment decisions.
    Rencz F; Poór AK; Péntek M; Holló P; Kárpáti S; Gulácsi L; Szegedi A; Remenyik É; Hidvégi B; Herszényi K; Jókai H; Beretzky Z; Brodszky V
    J Eur Acad Dermatol Venereol; 2018 May; 32(5):783-790. PubMed ID: 29114942
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Moderate Psoriasis: A Proposed Definition.
    Llamas-Velasco M; de la Cueva P; Notario J; Martínez-Pilar L; Martorell A; Moreno-Ramírez D
    Actas Dermosifiliogr; 2017 Dec; 108(10):911-917. PubMed ID: 28823420
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ustekinumab improves health-related quality of life in patients with moderate-to-severe psoriasis: results from the PHOENIX 1 trial.
    Lebwohl M; Papp K; Han C; Schenkel B; Yeilding N; Wang Y; Krueger GG
    Br J Dermatol; 2010 Jan; 162(1):137-46. PubMed ID: 19903183
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 30.